Published in Cancer Res on March 15, 2007
GammaH2AX and cancer. Nat Rev Cancer (2008) 9.77
Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer (2011) 3.55
H2AX: functional roles and potential applications. Chromosoma (2009) 2.27
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res (2010) 2.12
H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy. J Nucleic Acids (2010) 1.69
Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer. Nat Rev Cancer (2012) 1.45
Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Phys (2009) 1.19
Histone variants: emerging players in cancer biology. Cell Mol Life Sci (2013) 1.17
Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci (2008) 1.10
Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol (2010) 1.08
Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line. J Biol Chem (2010) 1.02
Expression and functionality of histone H2A variants in cancer. Oncotarget (2014) 0.95
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res (2009) 0.95
Soluble histone H2AX is induced by DNA replication stress and sensitizes cells to undergo apoptosis. Mol Cancer (2008) 0.90
Epstein-Barr virus essential antigen EBNA3C attenuates H2AX expression. J Virol (2014) 0.87
uPAR and cathepsin B inhibition enhanced radiation-induced apoptosis in gliomainitiating cells. Neuro Oncol (2012) 0.86
Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors. Oncotarget (2010) 0.86
Dietary fat-dependent transcriptional architecture and copy number alterations associated with modifiers of mammary cancer metastasis. Clin Exp Metastasis (2010) 0.85
MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest. Genes Cancer (2010) 0.81
Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway. Acta Pharmacol Sin (2012) 0.80
Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol (2014) 0.79
Defining the chromatin landscape in demyelinating disorders. Neurobiol Dis (2009) 0.77
The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors. Curr Opin Oncol (2014) 0.77
Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST). Oncotarget (2015) 0.77
Resveratrol induces apoptosis of human chronic myelogenous leukemia cells in vitro through p38 and JNK-regulated H2AX phosphorylation. Acta Pharmacol Sin (2015) 0.77
Epigenetics in gastrointestinal stromal tumors: clinical implications and potential therapeutic perspectives. Dig Dis Sci (2013) 0.77
Targeting Disease Persistence in Gastrointestinal Stromal Tumors. Stem Cells Transl Med (2015) 0.77
Gastrointestinal stromal tumors (GIST): facing cell death between autophagy and apoptosis. Autophagy (2017) 0.75
Proteomic profile of maternal-aged blastocoel fluid suggests a novel role for ubiquitin system in blastocyst quality. J Assist Reprod Genet (2016) 0.75
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell (2002) 9.36
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 6.43
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
Biology of gastrointestinal stromal tumors. J Clin Oncol (2004) 5.89
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44
BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res (2003) 4.17
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol (2007) 3.38
Concern The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist (2003) 3.36
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer (2008) 3.10
Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol (2004) 2.92
Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol (2002) 2.85
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol (2006) 2.81
Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med (2014) 2.80
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A (2010) 2.68
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature (2010) 2.65
KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol (2004) 2.51
Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res (2003) 2.32
Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res (2003) 2.32
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol (2006) 2.30
Gastrointestinal stromal tumors. Virchows Arch (2010) 2.28
Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci U S A (2003) 2.23
Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol (2002) 2.19
The forkhead-associated domain protein Cep170 interacts with Polo-like kinase 1 and serves as a marker for mature centrioles. Mol Biol Cell (2004) 2.17
Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol (2005) 2.12
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res (2006) 2.04
Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer (2007) 1.99
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer (2008) 1.99
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res (2009) 1.99
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol (2005) 1.98
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res (2007) 1.94
Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res (2008) 1.89
ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol (2008) 1.88
Characterization of the chromosomal translocation t(10;17)(q22;p13) in clear cell sarcoma of kidney. J Pathol (2012) 1.88
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A (2012) 1.86
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol (2012) 1.84
Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol (2012) 1.83
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene (2004) 1.82
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res (2004) 1.82
USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol (2004) 1.82
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A (2004) 1.81
Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res (2003) 1.81
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res (2007) 1.79
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer (2007) 1.76
Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics (2004) 1.76
Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res (2008) 1.73
Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A (2003) 1.73
USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res (2004) 1.64
Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res (2004) 1.63
Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res (2007) 1.57
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A (2012) 1.51
A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood (2009) 1.51
Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J Virol (2003) 1.49
Abrogation of the retinoblastoma tumor suppressor checkpoint during keratinocyte immortalization is not sufficient for induction of centrosome-mediated genomic instability. Cancer Res (2003) 1.48
Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. PLoS Pathog (2007) 1.45
Naive precursors of human regulatory T cells require FoxP3 for suppression and are susceptible to HIV infection. J Immunol (2008) 1.44
Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol Cell Biol (2003) 1.43
Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A (2006) 1.42
Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell (2006) 1.41
KIT mutations are common in testicular seminomas. Am J Pathol (2004) 1.36
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res (2008) 1.33
Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res (2002) 1.32
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene (2004) 1.30
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol (2010) 1.29
The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. J Virol (2007) 1.29
The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J Biol Chem (2006) 1.27
c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol (2009) 1.26
Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. Cancer Res (2010) 1.26
Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications. Am J Surg Pathol (2007) 1.25
Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol (2005) 1.25
Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res (2011) 1.25
ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer (2010) 1.24
The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma. Genes Chromosomes Cancer (2004) 1.24
Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer (2007) 1.24
Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development. J Exp Med (2004) 1.22
Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study. Mod Pathol (2005) 1.22
ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol (2012) 1.21
Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol (2010) 1.21
Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oncogene (2005) 1.21
Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol (2008) 1.20
A distant upstream locus control region is critical for expression of the Kit receptor gene in mast cells. Mol Cell Biol (2006) 1.20